<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7280142\results\search\disease\results.xml">
  <result pre="of Urology. pmcid: 7280142S2405-4569(20)30160-7 doi: 10.1016/j.euf.2020.06.002 : Article COVID-19 and" exact="Kidney" post="Disease: Molecular Determinants and Clinical Implications in Renal Cancer"/>
  <result pre="COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in" exact="Renal Cancer" post="MihalopoulosMeredithaâ€ DograNavneetbcâ€ MohamedNihalaBadaniKetanketan.badani@mountsinai.orgaâ�ŽKyprianouNatashaNatasha.Kyprianou@mountsinai.orgacdâ�Ž[a], [b], [c], [d], â�ŽCorresponding authors. Department"/>
  <result pre="and Kidney Disease: Molecular Determinants and Clinical Implications in Renal" exact="Cancer" post="MihalopoulosMeredithaâ€ DograNavneetbcâ€ MohamedNihalaBadaniKetanketan.badani@mountsinai.orgaâ�ŽKyprianouNatashaNatasha.Kyprianou@mountsinai.orgacdâ�Ž[a], [b], [c], [d], â�ŽCorresponding authors. Department"/>
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="the COVID-19 resource centre remains active. Abstract Context The severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic that erupted in"/>
  <result pre="COVID-19 resource centre remains active. Abstract Context The severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) pandemic that erupted in December"/>
  <result pre="resource centre remains active. Abstract Context The severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) pandemic that erupted in December 2019"/>
  <result pre="over 70 000 lives (by April 7, 2020). As the" exact="viral infection" post="is driven by increased angiotensin-converting enzyme-2 (ACE2) expression, with"/>
  <result pre="70 000 lives (by April 7, 2020). As the viral" exact="infection" post="is driven by increased angiotensin-converting enzyme-2 (ACE2) expression, with"/>
  <result pre="it is crucial to gain insights into the mechanisms underlying" exact="renal cell carcinoma" post="(RCC) and coronavirus disease 2019 (COVID-19). Objective This study"/>
  <result pre="crucial to gain insights into the mechanisms underlying renal cell" exact="carcinoma" post="(RCC) and coronavirus disease 2019 (COVID-19). Objective This study"/>
  <result pre="into the mechanisms underlying renal cell carcinoma (RCC) and coronavirus" exact="disease" post="2019 (COVID-19). Objective This study considers up-to-date information on"/>
  <result pre="considers up-to-date information on the biological determinants shared by COVID-19" exact="and renal disease," post="and aims to provide evidence-based recommendations for the clinical"/>
  <result pre="up-to-date information on the biological determinants shared by COVID-19 and" exact="renal disease," post="and aims to provide evidence-based recommendations for the clinical"/>
  <result pre="of Science). As of March 31, 2020, the Center for" exact="Disease" post="Control reported that of the adults hospitalized for COVID-19"/>
  <result pre="for COVID-19 with underlying conditions in the USA, 74.8% had" exact="chronic" post="renal disease. Evidence synthesis Evidence is discussed from epidemiological"/>
  <result pre="COVID-19 with underlying conditions in the USA, 74.8% had chronic" exact="renal disease." post="Evidence synthesis Evidence is discussed from epidemiological studies on"/>
  <result pre="of RCC and COVID-19 patients. Patient summary Amid the coronavirus" exact="disease" post="2019 (COVID-19) pandemic, patients diagnosed with renal cell carcinoma"/>
  <result pre="Amid the coronavirus disease 2019 (COVID-19) pandemic, patients diagnosed with" exact="renal cell carcinoma" post="and infected with severe acute respiratory syndrome coronavirus 2"/>
  <result pre="coronavirus disease 2019 (COVID-19) pandemic, patients diagnosed with renal cell" exact="carcinoma" post="and infected with severe acute respiratory syndrome coronavirus 2"/>
  <result pre="patients diagnosed with renal cell carcinoma and infected with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) may receive complimentary treatment"/>
  <result pre="diagnosed with renal cell carcinoma and infected with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) may receive complimentary treatment modalities"/>
  <result pre="with renal cell carcinoma and infected with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) may receive complimentary treatment modalities to"/>
  <result pre="Home Message This review provides novel biological insights into coronavirus" exact="disease" post="2019 (COVID-19)-infected patients with renal disease, with special emphasis"/>
  <result pre="novel biological insights into coronavirus disease 2019 (COVID-19)-infected patients with" exact="renal disease," post="with special emphasis on renal cell carcinoma and development"/>
  <result pre="2019 (COVID-19)-infected patients with renal disease, with special emphasis on" exact="renal cell carcinoma" post="and development of science-based action guidelines and therapeutic strategies"/>
  <result pre="patients with renal disease, with special emphasis on renal cell" exact="carcinoma" post="and development of science-based action guidelines and therapeutic strategies"/>
  <result pre="action guidelines and therapeutic strategies in the clinical management of" exact="renal cell carcinoma" post="patients diagnosed with COVID-19. Keywords Viral infection Renal tumors"/>
  <result pre="and therapeutic strategies in the clinical management of renal cell" exact="carcinoma" post="patients diagnosed with COVID-19. Keywords Viral infection Renal tumors"/>
  <result pre="management of renal cell carcinoma patients diagnosed with COVID-19. Keywords" exact="Viral" post="infection Renal tumors Therapeutic targeting Associate Editor: Malte Rieken"/>
  <result pre="of renal cell carcinoma patients diagnosed with COVID-19. Keywords Viral" exact="infection" post="Renal tumors Therapeutic targeting Associate Editor: Malte Rieken 1"/>
  <result pre="renal cell carcinoma patients diagnosed with COVID-19. Keywords Viral infection" exact="Renal" post="tumors Therapeutic targeting Associate Editor: Malte Rieken 1 Introduction"/>
  <result pre="February 2020, The World Health Organization (WHO) formally named the" exact="disease" post="triggered by 2019-nCoV as coronavirus disease 2019 (COVID-19). The"/>
  <result pre="(WHO) formally named the disease triggered by 2019-nCoV as coronavirus" exact="disease" post="2019 (COVID-19). The Internal Committee of Taxonomy of Viruses"/>
  <result pre="The Internal Committee of Taxonomy of Viruses then named the" exact="disease" post="severe respiratory syndrome coronavirus 2 (SARS-CoV-2), another Î²-coronavirus cluster"/>
  <result pre="Committee of Taxonomy of Viruses then named the disease severe" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), another Î²-coronavirus cluster related to"/>
  <result pre="of Taxonomy of Viruses then named the disease severe respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), another Î²-coronavirus cluster related to severe"/>
  <result pre="syndrome coronavirus 2 (SARS-CoV-2), another Î²-coronavirus cluster related to severe" exact="acute" post="respiratory syndrome (SARS) of 2003 and Middle East respiratory"/>
  <result pre="coronavirus 2 (SARS-CoV-2), another Î²-coronavirus cluster related to severe acute" exact="respiratory" post="syndrome (SARS) of 2003 and Middle East respiratory syndrome"/>
  <result pre="2 (SARS-CoV-2), another Î²-coronavirus cluster related to severe acute respiratory" exact="syndrome" post="(SARS) of 2003 and Middle East respiratory syndrome (MERS)"/>
  <result pre="severe acute respiratory syndrome (SARS) of 2003 and Middle East" exact="respiratory" post="syndrome (MERS) of 2012 [1], [2]. As of April"/>
  <result pre="acute respiratory syndrome (SARS) of 2003 and Middle East respiratory" exact="syndrome" post="(MERS) of 2012 [1], [2]. As of April 7,"/>
  <result pre="[3]. While investigations are intensified as to the mechanisms of" exact="viral" post="infectivity, person-to-person transmission of the virus includes droplet inhalation"/>
  <result pre="while others suffer from fatigue, dyspnea, nasal congestion, nausea, or" exact="diarrhea" post="[5]. Cases can worsen and lead to acute respiratory"/>
  <result pre="nausea, or diarrhea [5]. Cases can worsen and lead to" exact="acute" post="respiratory distress syndrome (ARDS) or pneumonia. However, diagnosis is"/>
  <result pre="or diarrhea [5]. Cases can worsen and lead to acute" exact="respiratory" post="distress syndrome (ARDS) or pneumonia. However, diagnosis is often"/>
  <result pre="[5]. Cases can worsen and lead to acute respiratory distress" exact="syndrome" post="(ARDS) or pneumonia. However, diagnosis is often complicated by"/>
  <result pre="pre-existing conditions, such as diabetes, hypertension, and pulmonary, cardiac, and" exact="kidney diseases" post="are considered to be at a higher risk of"/>
  <result pre="considered to be at a higher risk of developing severe" exact="disease" post="[4], [7], [8], [9], [10]. Owing to the immense"/>
  <result pre="[8], [9], [10]. Owing to the immense burden of the" exact="disease" post="on the health, livelihood, and economics of the global"/>
  <result pre="therapeutic strategies for the treatment of COVID-19. As millions of" exact="cancer" post="patients are fighting COVID-19, investigations into the incidence and"/>
  <result pre="and clinical management of COVID-19 in patients with cancer, including" exact="renal cell carcinoma" post="(RCC), are ongoing with intensity. This review aims to"/>
  <result pre="management of COVID-19 in patients with cancer, including renal cell" exact="carcinoma" post="(RCC), are ongoing with intensity. This review aims to"/>
  <result pre="current understanding of the impact of angiotensin-converting enzyme-2 (ACE2)-mediated SARS-CoV-2" exact="infection" post="on kidney function and the therapeutic targeting of underlying"/>
  <result pre="of Science). As of March 31, 2020, the Center for" exact="Disease" post="Control (CDC) reported that, of the adults hospitalized for"/>
  <result pre="for COVID-19 with underlying conditions in the USA, 74.8% had" exact="chronic" post="renal disease. 3 Evidence synthesis 3.1 Mechanisms of SARS-CoV-2"/>
  <result pre="COVID-19 with underlying conditions in the USA, 74.8% had chronic" exact="renal disease." post="3 Evidence synthesis 3.1 Mechanisms of SARS-CoV-2 infection The"/>
  <result pre="chronic renal disease. 3 Evidence synthesis 3.1 Mechanisms of SARS-CoV-2" exact="infection" post="The novel zoonotic coronavirus (CoV) SARS-CoV-2 belongs to the"/>
  <result pre="the Î²-coronaviruses batâ€�SLâ€�CoV ZC45 and batâ€�SLâ€�CoV ZXC2, and can cause" exact="infection" post="of lower respiratory track and pneumonia in humans. Fig."/>
  <result pre="batâ€�SLâ€�CoV ZC45 and batâ€�SLâ€�CoV ZXC2, and can cause infection of" exact="lower" post="respiratory track and pneumonia in humans. Fig. 1 The"/>
  <result pre="ZC45 and batâ€�SLâ€�CoV ZXC2, and can cause infection of lower" exact="respiratory" post="track and pneumonia in humans. Fig. 1 The SARS-CoV-2"/>
  <result pre="ZXC2, and can cause infection of lower respiratory track and" exact="pneumonia" post="in humans. Fig. 1 The SARS-CoV-2 genome. The 30"/>
  <result pre="for four structural proteins that are functionally involved in the" exact="infection" post="process. The four structural proteins include the membrane (M),"/>
  <result pre="for infection. 2019-nCOV = 2019 novel coronavirus; SARS-CoV-2 = severe" exact="acute" post="respiratory syndrome coronavirus 2; sgRNA = subgenomic RNA. Structural"/>
  <result pre="infection. 2019-nCOV = 2019 novel coronavirus; SARS-CoV-2 = severe acute" exact="respiratory" post="syndrome coronavirus 2; sgRNA = subgenomic RNA. Structural Spike"/>
  <result pre="2019-nCOV = 2019 novel coronavirus; SARS-CoV-2 = severe acute respiratory" exact="syndrome" post="coronavirus 2; sgRNA = subgenomic RNA. Structural Spike (S)"/>
  <result pre="severe acute respiratory syndrome coronavirus 2; sgRNA = subgenomic RNA." exact="Structural" post="Spike (S) proteins drive the entry of the CoVs"/>
  <result pre="cell and is regulated by androgens (Fig. 2 ). SARS-CoV" exact="infection" post="is dependent on the proteolytic activity of TMPRSS2 and"/>
  <result pre="endosome formation (4), and ultimately responsible for the release of" exact="viral" post="RNA into the cytoplasm of host cells causing virulence."/>
  <result pre="cells causing virulence. ACE2 = angiotensin-converting enzyme-2; SARS-CoV-2 = severe" exact="acute" post="respiratory syndrome coronavirus 2; TMPRSS2 = type-II transmembrane serine"/>
  <result pre="causing virulence. ACE2 = angiotensin-converting enzyme-2; SARS-CoV-2 = severe acute" exact="respiratory" post="syndrome coronavirus 2; TMPRSS2 = type-II transmembrane serine protease"/>
  <result pre="virulence. ACE2 = angiotensin-converting enzyme-2; SARS-CoV-2 = severe acute respiratory" exact="syndrome" post="coronavirus 2; TMPRSS2 = type-II transmembrane serine protease 2."/>
  <result pre="the downstream interaction of Ang II with the Ang II" exact="type I" post="(AT1) receptor, are used to treat hypertension and other"/>
  <result pre="Ang II type I (AT1) receptor, are used to treat" exact="hypertension" post="and other cardiovascular diseases [19]. While these treatments do"/>
  <result pre="I (AT1) receptor, are used to treat hypertension and other" exact="cardiovascular" post="diseases [19]. While these treatments do not directly modulate"/>
  <result pre="[21]. Further, ACE2 levels are elevated in patients with multiple" exact="cardiovascular" post="conditions, diabetes, and hypertension, those who are at a"/>
  <result pre="II or increasing the virulence of the virus in the" exact="heart" post="and lungs due to the increased ACE2 expression [10]."/>
  <result pre="[10]. Both ACE2 and TMPRSS2 are coexpressed on ciliated bronchial" exact="epithelial" post="cells and type II pneumocytes, epithelia of small intestine,"/>
  <result pre="and TMPRSS2 are coexpressed on ciliated bronchial epithelial cells and" exact="type II" post="pneumocytes, epithelia of small intestine, and podocytes and the"/>
  <result pre="making these organ sites easy routes for SARS-CoV and SARS-CoV-2" exact="infection" post="[23]. In particular, ACE2 expression is higher in the"/>
  <result pre="issues as well as assess the potential risk of developing" exact="kidney injury" post="once infected with COVID-19. 3.2 Epidemiology of COVID-19 and"/>
  <result pre="injury once infected with COVID-19. 3.2 Epidemiology of COVID-19 and" exact="cancer" post="The COVID-19 pandemic created unique circumstances and challenges for"/>
  <result pre="cancer The COVID-19 pandemic created unique circumstances and challenges for" exact="cancer" post="patients, including patients with renal cancer and their clinical"/>
  <result pre="unique circumstances and challenges for cancer patients, including patients with" exact="renal cancer" post="and their clinical providers across the clinical care continuum"/>
  <result pre="circumstances and challenges for cancer patients, including patients with renal" exact="cancer" post="and their clinical providers across the clinical care continuum"/>
  <result pre="providers across the clinical care continuum and management trajectory (ie," exact="cancer" post="diagnosis, treatment, follow-up care, end of life). Epidemiological evidence"/>
  <result pre="care, end of life). Epidemiological evidence so far indicates that" exact="cancer" post="patients have a higher risk of contracting COVID-19, developing"/>
  <result pre="mortality rate is significantly higher among SARS-CoV-2â€&quot;infected patients with active" exact="cancer" post="(28.6%) than in patients with other comorbidities. Older cancer"/>
  <result pre="active cancer (28.6%) than in patients with other comorbidities. Older" exact="cancer" post="survivors are more vulnerable to COVID-19 because of existing"/>
  <result pre="to COVID-19 because of existing chronic, comorbid health conditions (diabetes," exact="cardiovascular" post="diseases, and respiratory diseases) [26]. Cancer patients presenting at"/>
  <result pre="of existing chronic, comorbid health conditions (diabetes, cardiovascular diseases, and" exact="respiratory" post="diseases) [26]. Cancer patients presenting at clinics and hospitals"/>
  <result pre="comorbid health conditions (diabetes, cardiovascular diseases, and respiratory diseases) [26]." exact="Cancer" post="patients presenting at clinics and hospitals for cancer care"/>
  <result pre="diseases) [26]. Cancer patients presenting at clinics and hospitals for" exact="cancer" post="care might have increased exposure to other infected patients"/>
  <result pre="to increased risk of COVID-19, morbidity, and mortality. To reduce" exact="cancer" post="patientsâ€™ risk of exposure, difficult clinical decisions have to"/>
  <result pre="by physicians about for whom, how, and when to provide" exact="cancer" post="treatment and follow-up care [27]. However, delays in cancer"/>
  <result pre="provide cancer treatment and follow-up care [27]. However, delays in" exact="cancer" post="management might lead to missed opportunities for curative treatment"/>
  <result pre="to missed opportunities for curative treatment and increased risks of" exact="cancer" post="progression to metastasis, anxiety, and stress. For patients experiencing"/>
  <result pre="cancer progression to metastasis, anxiety, and stress. For patients experiencing" exact="metastatic" post="or recurrent cancer, considerations should include how such delays"/>
  <result pre="to metastasis, anxiety, and stress. For patients experiencing metastatic or" exact="recurrent" post="cancer, considerations should include how such delays may lead"/>
  <result pre="contamination, is likely to increase patient clinical care (eg, managing" exact="disease" post="and comorbidities), financial (eg, loss of job and medical"/>
  <result pre="and anxiety) needs, thus worsening the quality of life and" exact="emotional" post="well-being in a population already burdened by cancer and"/>
  <result pre="life and emotional well-being in a population already burdened by" exact="cancer" post="and treatment impact. To address some of these needs,"/>
  <result pre="delivery approaches may pose significant challenges, especially for patients with" exact="limited" post="access to Internet or computer skills [28]. For patients"/>
  <result pre="to Internet or computer skills [28]. For patients participating in" exact="cancer" post="clinical trials, forced stay home or quarantine complicates hospital"/>
  <result pre="will have significant implication for the patientâ€™s health [29]. For" exact="renal cancer" post="patients and patients with chronic renal disease in need"/>
  <result pre="have significant implication for the patientâ€™s health [29]. For renal" exact="cancer" post="patients and patients with chronic renal disease in need"/>
  <result pre="patientâ€™s health [29]. For renal cancer patients and patients with" exact="chronic" post="renal disease in need of blood transfusion or kidney"/>
  <result pre="health [29]. For renal cancer patients and patients with chronic" exact="renal disease" post="in need of blood transfusion or kidney or transplant,"/>
  <result pre="[29]. For renal cancer patients and patients with chronic renal" exact="disease" post="in need of blood transfusion or kidney or transplant,"/>
  <result pre="RCC is twofold: the first is the removal of the" exact="renal tumor" post="with negative surgical margins via either partial or radical"/>
  <result pre="is twofold: the first is the removal of the renal" exact="tumor" post="with negative surgical margins via either partial or radical"/>
  <result pre="of the renal tumor with negative surgical margins via either" exact="partial" post="or radical nephrectomy based on the tumor characteristics of"/>
  <result pre="margins via either partial or radical nephrectomy based on the" exact="tumor" post="characteristics of size and location. This can be accomplished"/>
  <result pre="is the preservation of renal function. Most guidelines agree that" exact="partial" post="nephrectomy should be performed for the renal mass when"/>
  <result pre="mass when feasible to maximally preserve kidney function and prevent" exact="end stage renal" post="disease. The COVID-19 pandemic has transformed the way we"/>
  <result pre="feasible to maximally preserve kidney function and prevent end stage" exact="renal disease." post="The COVID-19 pandemic has transformed the way we are"/>
  <result pre="transformed the way we are approaching the surgical treatment of" exact="kidney cancer." post="The recommendations to be followed to reduce this risk"/>
  <result pre="COVID-19. COVID-19 testing All patients planning to undergo surgery for" exact="kidney cancer" post="should be tested prior to surgery, depending on local"/>
  <result pre="COVID-19 testing All patients planning to undergo surgery for kidney" exact="cancer" post="should be tested prior to surgery, depending on local"/>
  <result pre="to delay surgery until full recovery of the patient and" exact="viral" post="shedding risk is reduced. Operating room personnel Limit personnel"/>
  <result pre="should be reduced by lowering cautery settings, application time, and" exact="total" post="duration of tissue desiccation. Special considerations for minimally invasive"/>
  <result pre="be minimized. Every effort should be made to suction any" exact="residual" post="CO2 at the end of procedure prior to tumor"/>
  <result pre="any residual CO2 at the end of procedure prior to" exact="tumor" post="extraction. A closed insufflation system should be used to"/>
  <result pre="should be implemented to the suction system. COVID-19 = coronavirus" exact="disease" post="2019; OR = operating room; PPE = personal protective"/>
  <result pre="= personal protective equipment. 3.4 COVID-19 impacts the kidney 3.4.1" exact="Chronic" post="renal injury As of March 31, 2020, the CDC"/>
  <result pre="for COVID-19 with underlying conditions in the USA, 74.8% had" exact="chronic" post="renal disease, but patients with chronic renal disease consisted"/>
  <result pre="COVID-19 with underlying conditions in the USA, 74.8% had chronic" exact="renal disease," post="but patients with chronic renal disease consisted of only"/>
  <result pre="the USA, 74.8% had chronic renal disease, but patients with" exact="chronic" post="renal disease consisted of only 3% of total cases"/>
  <result pre="USA, 74.8% had chronic renal disease, but patients with chronic" exact="renal disease" post="consisted of only 3% of total cases [26], [31]."/>
  <result pre="74.8% had chronic renal disease, but patients with chronic renal" exact="disease" post="consisted of only 3% of total cases [26], [31]."/>
  <result pre="patients with chronic renal disease consisted of only 3% of" exact="total" post="cases [26], [31]. A study from Washington found that"/>
  <result pre="admitted to the intensive care unit (ICU), five (21%) had" exact="chronic" post="kidney disease [32]. In the Lombardy region of Italy,"/>
  <result pre="to the intensive care unit (ICU), five (21%) had chronic" exact="kidney disease" post="[32]. In the Lombardy region of Italy, of 1591"/>
  <result pre="the intensive care unit (ICU), five (21%) had chronic kidney" exact="disease" post="[32]. In the Lombardy region of Italy, of 1591"/>
  <result pre="ICU patients with COVID-19 from 72 hospitals, 36 (3%) had" exact="chronic" post="kidney disease. Various studies from Wuhan, China, investigating the"/>
  <result pre="patients with COVID-19 from 72 hospitals, 36 (3%) had chronic" exact="kidney disease." post="Various studies from Wuhan, China, investigating the early stages"/>
  <result pre="of the pandemic found that 2â€&quot;4% of COVID-19 patients had" exact="chronic" post="renal failure [8], [25], [33]. However, in a lager"/>
  <result pre="the pandemic found that 2â€&quot;4% of COVID-19 patients had chronic" exact="renal failure" post="[8], [25], [33]. However, in a lager study of"/>
  <result pre="1099 cases from mainland China, only 0.7% of patients had" exact="chronic" post="renal failure [5]. Others have cautioned against the risk"/>
  <result pre="cases from mainland China, only 0.7% of patients had chronic" exact="renal failure" post="[5]. Others have cautioned against the risk of COVID-19"/>
  <result pre="individuals receive dialysis treatment and constitute a high-risk group for" exact="adult" post="respiratory distress syndrome [36]. Basile et al [37] studied"/>
  <result pre="receive dialysis treatment and constitute a high-risk group for adult" exact="respiratory" post="distress syndrome [36]. Basile et al [37] studied a"/>
  <result pre="treatment and constitute a high-risk group for adult respiratory distress" exact="syndrome" post="[36]. Basile et al [37] studied a single HD"/>
  <result pre="patients on HD and four of 33 staff members developed" exact="infections" post="in a 1-mo span from mid-January to -February. Patients"/>
  <result pre="to -February. Patients on HD with COVID-19 had less lymphopenia," exact="lower" post="serum levels of inflammatory cytokines, and milder clinical disease"/>
  <result pre="lymphopenia, lower serum levels of inflammatory cytokines, and milder clinical" exact="disease" post="than other patients with COVID-19 infection. Although six patients"/>
  <result pre="infection, the presumed causes of death were not related to" exact="pneumonia" post="but rather to cardiovascular diseases, cerebrovascular issues, and hyperkalemia"/>
  <result pre="of death were not related to pneumonia but rather to" exact="cardiovascular" post="diseases, cerebrovascular issues, and hyperkalemia [37]. The emerging recommendations"/>
  <result pre="the risk to other patients and healthcare personnel [34]. 3.4.2" exact="Acute" post="kidney injury In the previous SARS and MERS-CoV epidemics,"/>
  <result pre="risk to other patients and healthcare personnel [34]. 3.4.2 Acute" exact="kidney injury" post="In the previous SARS and MERS-CoV epidemics, acute kidney"/>
  <result pre="Acute kidney injury In the previous SARS and MERS-CoV epidemics," exact="acute" post="kidney injury (AKI) developed in 5â€&quot;15% of cases and"/>
  <result pre="kidney injury In the previous SARS and MERS-CoV epidemics, acute" exact="kidney injury" post="(AKI) developed in 5â€&quot;15% of cases and had a"/>
  <result pre="and had a high mortality rate (60â€&quot;90%) [34], [38], [39]." exact="Kidney" post="injury was also associated with an increased risk of"/>
  <result pre="have been found for the current SAS-CoV-2 pandemic. In a" exact="postpartum" post="study of patients from Wuhan from January to the"/>
  <result pre="Diao et al [9] showed that 27.06% (23/85) patients exhibited" exact="acute" post="renal failure. However, another study conducted in a similar"/>
  <result pre="et al [9] showed that 27.06% (23/85) patients exhibited acute" exact="renal failure." post="However, another study conducted in a similar time frame"/>
  <result pre="Wuhan did not have anyone to develop or die of" exact="acute" post="renal failure [33]. Several studies in China have tracked"/>
  <result pre="did not have anyone to develop or die of acute" exact="renal failure" post="[33]. Several studies in China have tracked the development"/>
  <result pre="of patients had proteinuria, 26.7% had hematuria, and 13â€&quot;14% had" exact="elevated serum" post="creatinine, elevated blood urea nitrogen (BUN), and estimated glomerular"/>
  <result pre="baseline serum creatinine, elevated baseline BUN, AKI stage, proteinuria, and" exact="hematuria" post="were independent risk factors for in-hospital death. The incidence"/>
  <result pre="risk than those without AKI, higher than that of comorbid" exact="chronic" post="illness (1.5 times more) [24]. Clinical evidence from Shanghai"/>
  <result pre="effect on podocytes, as podocyte injury induces heavy proteinuria [43]." exact="Increased" post="creatinine levels could also indicate indirect effects on renal"/>
  <result pre="function caused by the virus, such as hypoxia, shock, and" exact="rhabdomyolysis" post="[4], [8]. Specifically, the effects of CoV-infected ACE2 can"/>
  <result pre="[4], [8]. Specifically, the effects of CoV-infected ACE2 can cause" exact="kidney damage" post="through a heightened inflammatory response by depleting Ang 1â€&quot;7"/>
  <result pre="response by depleting Ang 1â€&quot;7 and Ang 1â€&quot;9 levels. A" exact="systemic" post="cytokine stormâ€&quot;induced inflammatory response can also cause multiple organ"/>
  <result pre="cause multiple organ damage [42], [44]. It is unlikely that" exact="kidney injury" post="arises from deposition of immune complex of viral antigen"/>
  <result pre="that kidney injury arises from deposition of immune complex of" exact="viral" post="antigen or virus-induced specific immunological effector mechanisms because glomeruli"/>
  <result pre="microscopy imaging has appeared normal in COVID-19 patients [38]. 3.4.3" exact="Renal" post="cancer In addition to chronic and acute renal injury,"/>
  <result pre="imaging has appeared normal in COVID-19 patients [38]. 3.4.3 Renal" exact="cancer" post="In addition to chronic and acute renal injury, renal"/>
  <result pre="in COVID-19 patients [38]. 3.4.3 Renal cancer In addition to" exact="chronic" post="and acute renal injury, renal cancer must also be"/>
  <result pre="patients [38]. 3.4.3 Renal cancer In addition to chronic and" exact="acute" post="renal injury, renal cancer must also be assessed when"/>
  <result pre="Renal cancer In addition to chronic and acute renal injury," exact="renal cancer" post="must also be assessed when evaluating the risk factors"/>
  <result pre="cancer In addition to chronic and acute renal injury, renal" exact="cancer" post="must also be assessed when evaluating the risk factors"/>
  <result pre="in 2018, although few studies have evaluated the incidence of" exact="renal cancer" post="in COVID-19 cases [45]. Liang et al [46] found"/>
  <result pre="2018, although few studies have evaluated the incidence of renal" exact="cancer" post="in COVID-19 cases [45]. Liang et al [46] found"/>
  <result pre="found that 18 of 1590 cases had a history of" exact="cancer" post="in hospitals throughout China, a rate higher than that"/>
  <result pre="in hospitals throughout China, a rate higher than that of" exact="cancer" post="in the overall Chinese population. Lung cancer was the"/>
  <result pre="higher than that of cancer in the overall Chinese population." exact="Lung cancer" post="was the most frequent type of cancer in the"/>
  <result pre="than that of cancer in the overall Chinese population. Lung" exact="cancer" post="was the most frequent type of cancer in the"/>
  <result pre="Chinese population. Lung cancer was the most frequent type of" exact="cancer" post="in the study population (28%), but one case had"/>
  <result pre="one case had a history of RCC. Additionally, patients with" exact="cancer" post="had a higher risk of severe complications than patients"/>
  <result pre="a higher risk of severe complications than patients without cancer;" exact="cancer" post="patients treated with chemotherapy or surgery had a higher"/>
  <result pre="considerations in decision making regarding the clinical care of a" exact="cancer" post="patient infected with the virus (Fig. 3 ). Fig."/>
  <result pre="infected with the virus (Fig. 3 ). Fig. 3 SARS-CoV-2" exact="infection" post="in renal disease and therapeutic targeting of RCC. The"/>
  <result pre="the virus (Fig. 3 ). Fig. 3 SARS-CoV-2 infection in" exact="renal disease" post="and therapeutic targeting of RCC. The top panel shows"/>
  <result pre="virus (Fig. 3 ). Fig. 3 SARS-CoV-2 infection in renal" exact="disease" post="and therapeutic targeting of RCC. The top panel shows"/>
  <result pre="of RCC. The top panel shows an overview of the" exact="primary" post="signaling targets of viral infection and their association with"/>
  <result pre="panel shows an overview of the primary signaling targets of" exact="viral infection" post="and their association with renal disease. The bottom panel"/>
  <result pre="shows an overview of the primary signaling targets of viral" exact="infection" post="and their association with renal disease. The bottom panel"/>
  <result pre="primary signaling targets of viral infection and their association with" exact="renal disease." post="The bottom panel shows a proposed schema of the"/>
  <result pre="the current therapeutic management (blocking ACE2 receptor pathway and hence" exact="viral" post="internalization into host cells) and prevention strategies (controlling inflammation"/>
  <result pre="consequently cell response to virulence) for COVID-19 patients with underlying" exact="renal disease." post="ACE2 = angiotensin-converting enzyme-2; COVID-19 = coronavirus disease 2019;"/>
  <result pre="underlying renal disease. ACE2 = angiotensin-converting enzyme-2; COVID-19 = coronavirus" exact="disease" post="2019; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2."/>
  <result pre="angiotensin-converting enzyme-2; COVID-19 = coronavirus disease 2019; SARS-CoV-2 = severe" exact="acute" post="respiratory syndrome coronavirus 2. 3.5 Therapeutic management of RCC"/>
  <result pre="enzyme-2; COVID-19 = coronavirus disease 2019; SARS-CoV-2 = severe acute" exact="respiratory" post="syndrome coronavirus 2. 3.5 Therapeutic management of RCC and"/>
  <result pre="COVID-19 = coronavirus disease 2019; SARS-CoV-2 = severe acute respiratory" exact="syndrome" post="coronavirus 2. 3.5 Therapeutic management of RCC and COVID-19"/>
  <result pre="causes angiogenesis and proliferation, mostly through the activation of the" exact="vascular" post="endothelial growth factor receptor (VEGFR) [47]. Antiangiogenesis treatment of"/>
  <result pre="paxopanib, were first to be approved for frontline treatment of" exact="metastatic" post="RCC (mRCC) [48]. The use of immune checkpoint inhibitors"/>
  <result pre="axitinib [53]. The efficacy of ICIs in conjugation with COVID-19" exact="infection" post="is under intense investigation. Recent evidence suggests that restoration"/>
  <result pre="of immunocompetence with ICIs impacts the development of cytokine release" exact="syndrome" post="and contributes to the severity of COVID-19 and ARDS"/>
  <result pre="the severity of COVID-19 and ARDS [54]. Additionally, CoV-related interstitial" exact="pneumonia" post="could be worsened by potential pneumological toxicity from anit-PD-1/PD-L1"/>
  <result pre="ICI agents. However, discontinuation of ICIs in patients with COVID-19" exact="infections" post="is not recommended due relatively better outcomes than in"/>
  <result pre="RAS blockades, such as ACEis and ARBs, can potentially reduce" exact="cancer" post="growth, lessen metastatic potential, and increase patient survival in"/>
  <result pre="as ACEis and ARBs, can potentially reduce cancer growth, lessen" exact="metastatic" post="potential, and increase patient survival in RCC [55], [56]."/>
  <result pre="RCC, and increased ACE activity has been associated with higher" exact="tumor" post="grades [57], [58]. While the decrease in degradation of"/>
  <result pre="bradykinin by ACEis may stimulate growth, survival, and migration of" exact="cancer" post="cells, these effects must ultimately be offset by the"/>
  <result pre="have antitumor effects by decreasing cell migration and invasion of" exact="cancer" post="cells and reducing tumor growth by decreasing VEGF [59],"/>
  <result pre="decreasing cell migration and invasion of cancer cells and reducing" exact="tumor" post="growth by decreasing VEGF [59], [60], [61]. Mechanistically, the"/>
  <result pre="2). There is the potential to increase an RCC patientâ€™s" exact="susceptibility to" post="a more severe form of the disease due to"/>
  <result pre="RCC patientâ€™s susceptibility to a more severe form of the" exact="disease" post="due to increased ACE2 to which the virus can"/>
  <result pre="have been developed for the treatment of various cancers including" exact="renal cancer." post="The drugs decrease the effects of endothelin peptide isoform"/>
  <result pre="effects of endothelin peptide isoform 1 (ET-1), which increases human" exact="tumor" post="growth via activation of epidermal growth factor receptor, and"/>
  <result pre="In this way, ERAs have been shown to be effective" exact="cancer" post="therapeutics [62]. ET-1 affects the kidney by binding to"/>
  <result pre="been shown to be promising agents in the treatment of" exact="chronic" post="kidney disease as well [62]. Consequential to its vasoconstrictive"/>
  <result pre="shown to be promising agents in the treatment of chronic" exact="kidney disease" post="as well [62]. Consequential to its vasoconstrictive action, the"/>
  <result pre="to be promising agents in the treatment of chronic kidney" exact="disease" post="as well [62]. Consequential to its vasoconstrictive action, the"/>
  <result pre="to its vasoconstrictive action, the endothelin axis usually affects portal" exact="arterial hypertension" post="(PAH), and ERAs are a common treatment against PAH"/>
  <result pre="its vasoconstrictive action, the endothelin axis usually affects portal arterial" exact="hypertension" post="(PAH), and ERAs are a common treatment against PAH"/>
  <result pre="is then the potential of ERAs to help those with" exact="hypertension" post="to defend themselves against COVID-19. 3.6 Stratification and screening"/>
  <result pre="and a powerful tool in obtaining a profile of the" exact="tumor" post="pathology [64], [65], [66]. Exosomes, cell-free (cf) DNA/RNA, and"/>
  <result pre="pathology [64], [65], [66]. Exosomes, cell-free (cf) DNA/RNA, and circulating" exact="tumor" post="cells (CTCs) are currently at the forefront of liquid"/>
  <result pre="assays in combination with microRNA and/or protein biomarkers to provide" exact="tumor" post="monitoring at high sensitivity and specificity [69]. Hence, RCC-associated"/>
  <result pre="an unequivocal future of NextGen-liquid biopsy as novel tools for" exact="disease" post="monitoring, biomarker discovery, and precision medicine. Recently, RCC-based liquid"/>
  <result pre="the US FDA for the prognosis and diagnosis of the" exact="disease" post="[70]. RCC-associated tumor-based CTCs and cfDNA are studied for"/>
  <result pre="for their genomic and epigenomic landscape, providing vital information about" exact="tumor" post="heterogeneity and tissue lineage [70]. Furthermore, two recent studies"/>
  <result pre="SARS-CoV-2 assessment suggests that urine contains almost no detectable COVID-19" exact="viral" post="RNA load, and only a small amount of viral"/>
  <result pre="COVID-19 viral RNA load, and only a small amount of" exact="viral" post="RNA copies are present in blood (current tool of"/>
  <result pre="followed by a reverse transcriptase polymerase chain reaction) [72]. However," exact="elevated serum" post="creatinine, BUN, and hematuria shown during hospitalization of COVID-19"/>
  <result pre="polymerase chain reaction) [72]. However, elevated serum creatinine, BUN, and" exact="hematuria" post="shown during hospitalization of COVID-19 patients are associated with"/>
  <result pre="associated with higher mortality, pointing to an indirect mechanism of" exact="kidney damage" post="in COVID-19â€&quot;infected patients [8]. This evidence supports that liquid"/>
  <result pre="options to cure COVID-19 For several of the patients with" exact="renal disease" post="and AKI, treatment course proceeds similarly to that of"/>
  <result pre="to cure COVID-19 For several of the patients with renal" exact="disease" post="and AKI, treatment course proceeds similarly to that of"/>
  <result pre="most COVID-19 cases, although we are following a learning curve." exact="General" post="management including quarantining, use of protective personal equipment, nutritional"/>
  <result pre="doses are associated with high mortality due to inhibition of" exact="viral" post="clearance and prolongation of the duration of viremia [34],"/>
  <result pre="sufficient breadth of treatment [75]. 3.7.2 Oligonucleotides Targeting the SARS-CoV-2" exact="viral" post="RNA genome for degradation may hold a promise, but"/>
  <result pre="but it is challenging during the current pandemic, considering that" exact="viral" post="RNA sequence domains are not known and limited targeted"/>
  <result pre="considering that viral RNA sequence domains are not known and" exact="limited" post="targeted delivery of the oligonucleotide to the lungs may"/>
  <result pre="COVID-19 [34], [77]. Remdesivir, a drug that interacts with the" exact="viral" post="polymerase, is clinically effective in treating MERS in mouse"/>
  <result pre="neutralize the endosome-lysosomal acidic pH, blocking protease activity and inhibiting" exact="viral" post="entry into the cell (Fig. 2). Endosome-lysosomal protease inhibitors"/>
  <result pre="of a recovered patient can provide polyclonal antibodies to different" exact="viral" post="antigens of SARS-CoV-2, which can help treat patients who"/>
  <result pre="decrease ACE2 levels in the lungs during infection, thus impacting" exact="acute" post="respiratory distress pathophysiology [75]. Testing for the efficacy and"/>
  <result pre="ACE2 levels in the lungs during infection, thus impacting acute" exact="respiratory" post="distress pathophysiology [75]. Testing for the efficacy and safety"/>
  <result pre="patients to enable new insights into the downstream effect of" exact="viral" post="damage on renal function. Liquid biopsy could be the"/>
  <result pre="research efforts escalate globally toward the eradication of COVID-19 in" exact="cancer" post="patients, our team joins the battle, driven by science-based"/>
  <result pre="genome structure, replication, and pathogenesisJ Med Virol92202041842331967327 3World Health OrganizationCoronavirus" exact="disease" post="2019 (COVID-19) situation reportâ€&quot;782020 4PericoL.BenigniA.RemuzziG.Should COVID-19 concern nephrologists? Why"/>
  <result pre="The emerging impasse of angiotensin blockadeNephron24126202019 5GuanW.NiZ.HuY.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J Med38220201708172032109013 6ChenN.ZhouM.DongX.Epidemiological and clinical"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet395202050751332007143 7PatelA.B.VermaA.COVID-19 and angiotensin-converting"/>
  <result pre="inhibitors and angiotensin receptor blockers: what is the evidence?JAMA323202017691770 8ChengY.LuoR.WangK.Kidney" exact="disease" post="is associated with in-hospital death of patients with COVID-19Kidney"/>
  <result pre="et al. Human kidney is a target for novel severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv. In press."/>
  <result pre="al. Human kidney is a target for novel severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv. In press. 10.1101/2020.03.04.20031120."/>
  <result pre="Human kidney is a target for novel severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection. medRxiv. In press. 10.1101/2020.03.04.20031120. 10Hanff"/>
  <result pre="of the ACE2/angiotensin 1â€&quot;7 axis of the renin-angiotensin system in" exact="heart" post="failureCirc Res11820161313132627081112 15AnguianoL.RieraM.PascualJ.SolerM.J.Circulating ACE2 in cardiovascular and kidney diseasesCurr"/>
  <result pre="the renin-angiotensin system in heart failureCirc Res11820161313132627081112 15AnguianoL.RieraM.PascualJ.SolerM.J.Circulating ACE2 in" exact="cardiovascular" post="and kidney diseasesCurr Med Chem2420173231324128413960 16de Farias LelisD.de FreitasD.F.MachadoA.S.CrespoT.S.SantosS.H.S.Angiotensin-(1-7),"/>
  <result pre="Chem2420173231324128413960 16de Farias LelisD.de FreitasD.F.MachadoA.S.CrespoT.S.SantosS.H.S.Angiotensin-(1-7), adipokines and inflammationMetabolism952019364530905634 17GonzalezL.NovoaU.MoyaJ.Angiotensin-(1-9) reduces" exact="cardiovascular" post="and renal inflammation in experimental renin-independent hypertensionBiochem Pharmacol156201835737030179588 18DonoghueM.HsiehF.BaronasE.A"/>
  <result pre="attenuates cardiac fibrosis in streptozotocin-induced diabetic ratsCardiology13120159710625896805 22ZhengY.Y.MaY.T.ZhangJ.Y.XieX.COVID-19 and the" exact="cardiovascular" post="systemNat Rev Cardiol17202025926032139904 23Xu D, Zhang H, Zhou W,"/>
  <result pre="Wang LH, Cui XG. Identification of a potential mechanism of" exact="acute" post="kidney injury during the COVID-19 outbreak : a study"/>
  <result pre="LH, Cui XG. Identification of a potential mechanism of acute" exact="kidney injury" post="during the COVID-19 outbreak : a study based on"/>
  <result pre="25WangD.HuB.HuC.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA323202010611069 26CDC COVID-19 Response TeamPreliminary estimates of"/>
  <result pre="prevalence of selected underlying health conditions among patients with coronavirus" exact="disease" post="2019â€&quot;United States, February 12â€&quot;March 28, 2020MMWR Morb Mortal Wkly"/>
  <result pre="States, February 12â€&quot;March 28, 2020MMWR Morb Mortal Wkly Rep69202038238632240123 27UedaM.MartinsR.HendrieP.C.Managing" exact="cancer" post="care during the COVID-19 pandemic: agility and collaboration toward"/>
  <result pre="Med38220202012202232227758 33Wang L, Li X, Chen H, et al. SARS-CoV-2" exact="infection" post="does not significantly cause acute renal injury: an analysis"/>
  <result pre="Chen H, et al. SARS-CoV-2 infection does not significantly cause" exact="acute" post="renal injury: an analysis of 116 hospitalized patients with"/>
  <result pre="and long term conditions: what if you have cancer, diabetes," exact="or chronic" post="kidney disease?BMJ3682020m117432213482 36KligerA.S.SilberzweigJ.Mitigating Risk of COVID-19 in Dialysis FacilitiesClin"/>
  <result pre="long term conditions: what if you have cancer, diabetes, or" exact="chronic" post="kidney disease?BMJ3682020m117432213482 36KligerA.S.SilberzweigJ.Mitigating Risk of COVID-19 in Dialysis FacilitiesClin"/>
  <result pre="haemodialysis centresNephrol Dial Transplant35202073774132196116 38ChuK.H.TsangW.K.TangC.S.Acute renal impairment in coronavirus-associated severe" exact="acute" post="respiratory syndromeKidney Int672006698705 39BetjesM.G.H.Immune cell dysfunction and inflammation in"/>
  <result pre="centresNephrol Dial Transplant35202073774132196116 38ChuK.H.TsangW.K.TangC.S.Acute renal impairment in coronavirus-associated severe acute" exact="respiratory" post="syndromeKidney Int672006698705 39BetjesM.G.H.Immune cell dysfunction and inflammation in end-stage"/>
  <result pre="dysfunction and inflammation in end-stage renal diseaseNat Rev Nephrol9201325526523507826 40JungJ.Y.ParkB.H.HongS.B.Acute" exact="kidney injury" post="in critically ill patients with pandemic influenza A pneumonia"/>
  <result pre="kidney injury in critically ill patients with pandemic influenza A" exact="pneumonia" post="2009 in Korea: a multicenter studyJ Crit Care26201157758521489748 41Cao"/>
  <result pre="coronavirus in Wuhan, ChinaLancet395202049750631986264 43JeffersonJ.A.NelsonP.J.NajafianB.ShanklandS.J.Podocyte disorders: core curriculum 2011Am J" exact="Kidney" post="Dis58201166667721868143 44HuangK.J.SuI.J.TheronM.An interferon-Î³-related cytokine storm in SARS patientsJ Med"/>
  <result pre="interferon-Î³-related cytokine storm in SARS patientsJ Med Virol75200518519415602737 45CapitanioU.BensalahK.BexA.Epidemiology of" exact="renal cell" post="carcinomaEur Urol752019748430243799 46LiangW.GuanW.ChenR.Cancer patients in SARS-CoV-2 infection: a nationwide"/>
  <result pre="tumourigenesisTrends Mol Med10200446647215350900 48NÃ©grierS.RaymondE.Antiangiogenic treatments and mechanisms of action in" exact="renal cell" post="carcinomaInvest New Drugs3020121791180121573959 49AounF.RassyE.E.AssiT.KattanJ.PDL-1/PD1 inhibitors: antibody or antinobody?Future Oncol1320171669167128831825"/>
  <result pre="New Drugs3020121791180121573959 49AounF.RassyE.E.AssiT.KattanJ.PDL-1/PD1 inhibitors: antibody or antinobody?Future Oncol1320171669167128831825 50LabriolaM.K.ZhuJ.GuptaR.Characterization of" exact="tumor" post="mutation burden, PD-L1 and DNA repair genes to assess"/>
  <result pre="genes to assess relationship to immune checkpoint inhibitors response in" exact="metastatic" post="renal cell carcinomaJ Immunother Cancer82020e000319 51EscudierB.PortaC.SchmidingerM.Renal cell carcinoma: ESMO"/>
  <result pre="to assess relationship to immune checkpoint inhibitors response in metastatic" exact="renal cell" post="carcinomaJ Immunother Cancer82020e000319 51EscudierB.PortaC.SchmidingerM.Renal cell carcinoma: ESMO clinical practice"/>
  <result pre="and follow-upAnn Oncol272016v586827664262 52AlbigesL.PowlesT.StaehlerM.Updated European Association of Urology guidelines on" exact="renal cell" post="carcinoma: immune checkpoint inhibition is the new backbone in"/>
  <result pre="checkpoint inhibition is the new backbone in first-line treatment of" exact="metastatic" post="clear-cell renal cell carcinomaEur Urol76201915115631151678 53RassyE.FlippotR.AlbigesL.Tyrosine kinase inhibitors and"/>
  <result pre="is the new backbone in first-line treatment of metastatic clear-cell" exact="renal cell" post="carcinomaEur Urol76201915115631151678 53RassyE.FlippotR.AlbigesL.Tyrosine kinase inhibitors and immunotherapy combinations in"/>
  <result pre="cell carcinomaEur Urol76201915115631151678 53RassyE.FlippotR.AlbigesL.Tyrosine kinase inhibitors and immunotherapy combinations in" exact="renal cell" post="carcinomaTher Adv Med Oncol122018113 54BersanelliM.Controversies about COVID-19 and anticancer"/>
  <result pre="treatment with immune checkpoint inhibitorsImmunotherapy12202026927332212881 55SobczukP.SzczylikC.PortaC.CzarneckaA.M.Renin angiotensin system deregulation as" exact="renal cancer" post="risk factor (Review)Oncol Lett1420175059506829098020 56AraÃºjoW.F.NavesM.A.RavaniniJ.N.SchorN.TeixeiraV.P.C.Renin-angiotensin system (RAS) blockade attenuates"/>
  <result pre="with immune checkpoint inhibitorsImmunotherapy12202026927332212881 55SobczukP.SzczylikC.PortaC.CzarneckaA.M.Renin angiotensin system deregulation as renal" exact="cancer" post="risk factor (Review)Oncol Lett1420175059506829098020 56AraÃºjoW.F.NavesM.A.RavaniniJ.N.SchorN.TeixeiraV.P.C.Renin-angiotensin system (RAS) blockade attenuates"/>
  <result pre="factor (Review)Oncol Lett1420175059506829098020 56AraÃºjoW.F.NavesM.A.RavaniniJ.N.SchorN.TeixeiraV.P.C.Renin-angiotensin system (RAS) blockade attenuates growth and" exact="metastatic" post="potential of renal cell carcinoma in miceUrol Oncol Semin"/>
  <result pre="56AraÃºjoW.F.NavesM.A.RavaniniJ.N.SchorN.TeixeiraV.P.C.Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of" exact="renal cell carcinoma" post="in miceUrol Oncol Semin Orig Investig332015389.e1389.e7 57Dolley-HitzeT.JouanF.MartinB.Angiotensin-2 receptors (AT1-R"/>
  <result pre="(RAS) blockade attenuates growth and metastatic potential of renal cell" exact="carcinoma" post="in miceUrol Oncol Semin Orig Investig332015389.e1389.e7 57Dolley-HitzeT.JouanF.MartinB.Angiotensin-2 receptors (AT1-R"/>
  <result pre="Pept165201021822320692300 59NiL.FengY.WanH.Angiotensin-(1-7) inhibits the migration and invasion of A549 human" exact="lung adenocarcinoma" post="cells through inactivation of the PI3K/Akt and MAPK signaling"/>
  <result pre="59NiL.FengY.WanH.Angiotensin-(1-7) inhibits the migration and invasion of A549 human lung" exact="adenocarcinoma" post="cells through inactivation of the PI3K/Akt and MAPK signaling"/>
  <result pre="of the PI3K/Akt and MAPK signaling pathwaysOncol Rep27201278379022089256 60Soto-PantojaD.R.MenonJ.GallagherP.E.TallantE.A.Angiotensin-(1-7) inhibits" exact="tumor" post="angiogenesis in human lung cancer xenografts with a reduction"/>
  <result pre="MAPK signaling pathwaysOncol Rep27201278379022089256 60Soto-PantojaD.R.MenonJ.GallagherP.E.TallantE.A.Angiotensin-(1-7) inhibits tumor angiogenesis in human" exact="lung cancer" post="xenografts with a reduction in vascular endothelial growth factorMol"/>
  <result pre="signaling pathwaysOncol Rep27201278379022089256 60Soto-PantojaD.R.MenonJ.GallagherP.E.TallantE.A.Angiotensin-(1-7) inhibits tumor angiogenesis in human lung" exact="cancer" post="xenografts with a reduction in vascular endothelial growth factorMol"/>
  <result pre="angiogenesis in human lung cancer xenografts with a reduction in" exact="vascular" post="endothelial growth factorMol Cancer Ther820091676168319509262 61GallagherP.E.TallantE.A.Inhibition of human lung"/>
  <result pre="cancer xenografts with a reduction in vascular endothelial growth factorMol" exact="Cancer" post="Ther820091676168319509262 61GallagherP.E.TallantE.A.Inhibition of human lung cancer cell growth by"/>
  <result pre="in vascular endothelial growth factorMol Cancer Ther820091676168319509262 61GallagherP.E.TallantE.A.Inhibition of human" exact="lung cancer" post="cell growth by angiotensin-(1-7)Carcinogenesis2520042045205215284177 62EnevoldsenF.C.SahanaJ.WehlandM.GrimmD.InfangerM.KrÃ¼gerM.Endothelin receptor antagonists: status quo"/>
  <result pre="vascular endothelial growth factorMol Cancer Ther820091676168319509262 61GallagherP.E.TallantE.A.Inhibition of human lung" exact="cancer" post="cell growth by angiotensin-(1-7)Carcinogenesis2520042045205215284177 62EnevoldsenF.C.SahanaJ.WehlandM.GrimmD.InfangerM.KrÃ¼gerM.Endothelin receptor antagonists: status quo"/>
  <result pre="63HoudeM.DesbiensL.Dâ€™OrlÃ©ans-JusteP.Endothelin-1: biosynthesis, signaling and vasoreactivityAdv Pharmacol77201614317527451097 64DiazL.A.BardelliA.Liquid biopsies: genotyping circulating" exact="tumor" post="DNAJ Clin Oncol32201457958624449238 65SmithJ.T.WunschB.H.DograN.Integrated nanoscale deterministic lateral displacement arrays"/>
  <result pre="from clinically-relevant volumes of biological samplesLab Chip1820183913392530468237 66StottS.L.HsuC.H.TsukrovD.I.Isolation of circulating" exact="tumor" post="cells using a microvortex-generating herringbone-chipProc Natl Acad Sci U"/>
  <result pre="69RedovaM.PoprachA.NekvindovaJ.Circulating miR-378 and miR-451 in serum are potential biomarkers for" exact="renal cell" post="carcinomaJ Transl Med10120125510.1186/1479-5876-10-5522440013 70KarachaliouN.Mayo-de-las-CasasC.Molina-VilaM.A.RosellR.Real-time liquid biopsies become a reality"/>
  <result pre="carcinomaJ Transl Med10120125510.1186/1479-5876-10-5522440013 70KarachaliouN.Mayo-de-las-CasasC.Molina-VilaM.A.RosellR.Real-time liquid biopsies become a reality in" exact="cancer" post="treatmentAnn Transl Med320152425705634 71RaimondoF.MorosiL.CorbettaS.Differential protein profiling of renal cell"/>
  <result pre="reality in cancer treatmentAnn Transl Med320152425705634 71RaimondoF.MorosiL.CorbettaS.Differential protein profiling of" exact="renal cell carcinoma" post="urinary exosomesMol Biosyst920131220123323511837 72WangW.XuY.GaoR.Detection of SARS-CoV-2 in different types"/>
  <result pre="cancer treatmentAnn Transl Med320152425705634 71RaimondoF.MorosiL.CorbettaS.Differential protein profiling of renal cell" exact="carcinoma" post="urinary exosomesMol Biosyst920131220123323511837 72WangW.XuY.GaoR.Detection of SARS-CoV-2 in different types"/>
  <result pre="course and outcomes of critically Ill patients with Middle East" exact="respiratory" post="syndrome coronavirus infectionAnn Intern Med160201438939724474051 74RussellC.D.MillarJ.E.BaillieJ.K.Clinical evidence does not"/>
  <result pre="and outcomes of critically Ill patients with Middle East respiratory" exact="syndrome" post="coronavirus infectionAnn Intern Med160201438939724474051 74RussellC.D.MillarJ.E.BaillieJ.K.Clinical evidence does not support"/>
 </snippets>
</snippetsTree>
